Article
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy - 16 Feb 2023
Cabot Gabriel, Kim Kihun, Mark Brian L, Oliver Antonio, Khajehpour Mazdak
Abstract excerpt
Several Pseudomonas aeruginosa AmpC mutants have emerged that exhibit enhanced activity against ceftazidime and ceftolozane, while also evading inhibition by avibactam. Interestingly, P. aeruginosa strains harboring these AmpC mutations fortuitously exhibit enhanced carbapenem susceptibility. This acquired susceptibility was investigated by comparing the degradation of imipenem by wild-type and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
